Trial Profile
Efficacy and Safety of Sofosbuvir Plus Daclatasvir With or Without Ribavirin: Large Real-life Results of Patients With Chronic Hepatitis C Genotype 4
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 19 May 2020
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 13 Nov 2017 New trial record
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases